MX2009012838A - Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo. - Google Patents

Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.

Info

Publication number
MX2009012838A
MX2009012838A MX2009012838A MX2009012838A MX2009012838A MX 2009012838 A MX2009012838 A MX 2009012838A MX 2009012838 A MX2009012838 A MX 2009012838A MX 2009012838 A MX2009012838 A MX 2009012838A MX 2009012838 A MX2009012838 A MX 2009012838A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
labeled
composition
tumor antigen
nir fluorescence
Prior art date
Application number
MX2009012838A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Max Hasmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009012838A publication Critical patent/MX2009012838A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición de un anticuerpo monoclonal no marcado que se aglutina a un antígeno tumoral y a un segundo anticuerpo monoclonal marcado con un marcador fluorescente de NIR, que se aglutina al mismo antígeno tumoral, en donde el primer y segundo anticuerpos no exhiben reactividad cruzada. La composición puede ser utilizada para el tratamiento de los pacientes que padecen de tumores sólidos que están asociados con una sobre-expresión de tal antígeno tumoral. La invención se refiere además a la co-administración del primer y segundo anticuerpos así como a un método de adquisición de imágenes por fluorescencia de NIR de tales tumores o de los pacientes que padecen de tales tumores durante el tratamiento del paciente con tal composición.
MX2009012838A 2007-06-06 2008-06-04 Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo. MX2009012838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07011087 2007-06-06
PCT/EP2008/004456 WO2008148546A2 (en) 2007-06-06 2008-06-04 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label

Publications (1)

Publication Number Publication Date
MX2009012838A true MX2009012838A (es) 2009-12-11

Family

ID=38658220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012838A MX2009012838A (es) 2007-06-06 2008-06-04 Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.

Country Status (12)

Country Link
US (2) US8529901B2 (es)
EP (1) EP2155786B1 (es)
JP (1) JP5373776B2 (es)
KR (1) KR101169243B1 (es)
CN (1) CN101679510A (es)
AU (1) AU2008258859A1 (es)
BR (1) BRPI0812777A2 (es)
CA (1) CA2687819A1 (es)
ES (1) ES2555784T3 (es)
IL (1) IL201565A0 (es)
MX (1) MX2009012838A (es)
WO (1) WO2008148546A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
UA95902C2 (ru) * 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2012012736A (es) * 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
CN103154035B (zh) 2010-05-27 2017-05-10 根马布股份公司 针对her2的单克隆抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP6385060B2 (ja) * 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
CN102262155B (zh) * 2011-04-12 2013-10-09 百泰生物药业有限公司 重组人表皮生长因子生物学活性测定方法及其应用
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
LT2766040T (lt) 2011-10-14 2019-08-12 F. Hoffmann-La Roche Ag Pertuzumabas, trastuzumabas, docetakselis ir karboplatina, skirti ankstyvos stadijos krūties vėžiui gydyti
RU2014137125A (ru) * 2012-03-30 2016-05-27 Клариент Дайагностик Сервисез, Инк. Способы формирования изображения биологического образца
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
AU2015249633B2 (en) 2014-04-25 2020-10-15 Genentech, Inc. Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20190119259A1 (en) * 2015-12-10 2019-04-25 City Of Hope Cell penetrating cyanine-coupled antibodies
KR101847264B1 (ko) * 2016-03-29 2018-04-10 국립암센터 항원 반응형 항체-형광염료 결합체 및 이를 이용한 표적 세포의 형광영상 검출방법
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
JP7375821B2 (ja) * 2019-08-27 2023-11-08 株式会社島津製作所 治療支援装置および治療支援装置の作動方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US7776612B2 (en) * 2001-04-13 2010-08-17 Chugai Seiyaku Kabushiki Kaisha Method of quantifying antigen expression
CN103981190A (zh) 2005-02-07 2014-08-13 罗氏格黎卡特股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用

Also Published As

Publication number Publication date
KR101169243B1 (ko) 2012-08-02
CA2687819A1 (en) 2008-12-11
WO2008148546A2 (en) 2008-12-11
JP5373776B2 (ja) 2013-12-18
JP2010529060A (ja) 2010-08-26
EP2155786B1 (en) 2015-11-18
WO2008148546A3 (en) 2009-02-19
US9687568B2 (en) 2017-06-27
AU2008258859A1 (en) 2008-12-11
US20110027190A1 (en) 2011-02-03
ES2555784T3 (es) 2016-01-08
BRPI0812777A2 (pt) 2014-12-02
US20130323180A1 (en) 2013-12-05
IL201565A0 (en) 2010-05-31
CN101679510A (zh) 2010-03-24
US8529901B2 (en) 2013-09-10
KR20100003371A (ko) 2010-01-08
EP2155786A2 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
MX2009012838A (es) Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007081680A3 (en) Microrna expression abnormalities in pancreatic endocrine and acinar tumors
WO2009112245A9 (en) Antibody against the csf-1 r
MX2008007502A (es) Anticuerpos anti mn y metodos para su utilizacion.
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
NZ596834A (en) Prlr-specific antibody and uses thereof
UA94707C2 (en) Antigen-binding molecule capable of binding to plgf
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
IL186775A0 (en) Tgf beta 1 specific antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2007137279A3 (en) Herv-k antigens, antibodies, and methods
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2010104598A3 (en) Kinase protein binding inhibitors
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2008110379A3 (en) Monoclonal antibodies for treatment of cancer
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration